Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EnBio HoldingsTSE:6092 -0.83%58 Debt-to-EBITDA is 2.44 as of Mar. 2026, which is 65% below its 10-year median of 7.02. GuruFocus rates TSE:6092 with a GF Score™ of 58/100 and a GF Value™ of 円807.22 (Fairly Valued). The stock has 7 warning signs investors should review. Among 835 Business Services companies, EnBio Holdings ranks worse than 83.71% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for EnBio Holdings's Debt-to-EBITDA or its related term are showing as below:
TSE:6092'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 5.06 Med: 7.02 Max: 20.78
Current: 5.09
During the past 13 years, the highest Debt-to-EBITDA Ratio of EnBio Holdings was 20.78. The lowest was 5.06. And the median was 7.02.
TSE:6092's Debt-to-EBITDA is ranked worse than 83.71% of 835
companies
in the Business Services industry
Industry Median: 1.67
vs TSE:6092: 5.09
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
EnBio Holdings Debt-to-EBITDA Related Terms
EnBio Holdings Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for EnBio Holdings's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:6092 vs CTAS, CPRT, GPN: Debt-to-EBITDA Comparison
For the Specialty Business Services subindustry, EnBio Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EnBio Holdings Debt-to-EBITDA vs Business Services Industry
For the Business Services industry and Industrials sector, EnBio Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where EnBio Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
EnBio Holdings (TSE:6092) has a Debt-to-EBITDA of 2.44 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on EnBio Holdings. This is 65% below median its historical median of 7.02. Over the past decade, EnBio Holdings' Debt-to-EBITDA has ranged from 5.06 to 20.78. According to the industry distribution chart, EnBio Holdings ranks #699 out of 835 companies in the Business Services industry, placing it in the top 83.7%.
Is EnBio Holdings' Debt-to-EBITDA too high?
EnBio Holdings' current Debt-to-EBITDA of 2.44 is 65% below median its 10-year median of 7.02. Over the past 10 years, this metric has ranged from a low of 5.06 to a high of 20.78. The Business Services industry median Debt-to-EBITDA is 1.67. EnBio Holdings' value of 2.44 is 46.1% above this industry median. Based on the distribution chart, EnBio Holdings ranks #699 out of 835 companies in the Business Services industry, which is in the bottom quartile relative to peers. Overall, EnBio Holdings has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does EnBio Holdings' Debt-to-EBITDA compare to CTAS and CPRT?
According to the Business Services industry distribution chart, EnBio Holdings ranks #699 out of 835 companies for Debt-to-EBITDA. This places EnBio Holdings in the lower half of its industry. The industry median Debt-to-EBITDA is 1.67. EnBio Holdings' value of 2.44 is 46.1% above this benchmark. Historically, EnBio Holdings' own Debt-to-EBITDA has ranged from 5.06 to 20.78 over the past decade. While the company's 10-year median is 7.02 vs. the industry median of 1.67, EnBio Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Business Services company?
The median Debt-to-EBITDA among Business Services companies is 1.67, based on 835 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EnBio Holdings's current Debt-to-EBITDA of 2.44 is 46.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on EnBio Holdings. For the Business Services industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EnBio Holdings's current Debt-to-EBITDA is 2.44, which is 65% below median its own 10-year median of 7.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EnBio Holdings stock overvalued right now?
Based on GuruFocus' analysis, EnBio Holdings (TSE:6092) is currently considered Fairly Valued. The stock's GF Value™ is 円807.22, compared to a current price of 円837.00 — trading 3.7% above its estimated fair value. The current Debt-to-EBITDA is 2.44, which is 65% below median its 10-year median of 7.02 and 46.1% above the Business Services industry median of 1.67. EnBio Holdings' overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For EnBio Holdings (TSE:6092), the current Debt-to-EBITDA is 2.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EnBio Holdings (TSE:6092) Overvalued in 2026?
Based on GuruFocus' analysis, EnBio Holdings stock appears to be overvalued.
The current stock price of 円837.00 is trading 3.7% above its estimated GF Value™ of 円807.22.
GuruFocus considers EnBio Holdings to be Fairly Valued.
Key valuation signals for TSE:6092:
Debt-to-EBITDA: 2.44 (65% below median its 10-year median of 7.02)
GF Value™: 円807.22 vs. price of 円837.00 (3.7% above fair value)
Industry Position: 46.1% above the Business Services median (#699 of 835)
No single metric tells the full story. See the TSE:6092 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EnBio Holdings Inc is a Japanese company engaged in environmental solution business, tools and chemicals business, and brownfield revitalization business. The environmental business involves investigation, remediation and risk management consulting of contaminated soil and groundwater; Tools and chemicals business involves sales of chemicals used for environmental work such as site investigation and remediation; and brownfield revitalization business which involves purchasing and regeneration of brownfields. The objective of the company is solving soil and groundwater contamination issues.
58GF Score
Get the complete analysis for TSE:6092
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6092 has been successfully added to your 
